-
公开(公告)号:US20230313107A1
公开(公告)日:2023-10-05
申请号:US18147356
申请日:2022-12-28
发明人: Andrew W. McFarland , Peter J. Beemiller , Guido K. Stadler , Alexander J. Mastroianni , Joshua J. Cardiel Rivera , Darcy K. Kelly-Greene , Jonathan Cloud Dragon Hubbard , Natalie C. Marks , Long Van Le , Ke-Chih Lin
IPC分类号: C12M1/00 , C12M3/06 , C12M3/00 , C12M1/34 , C12N5/0783
CPC分类号: C12M29/10 , C12M23/16 , C12M23/40 , C12M23/42 , C12M41/12 , C12M41/36 , C12N5/0636 , B01L2300/0883
摘要: Cartridge for manufacturing a population of cells suitable for formulation as a cellular therapeutic are disclosed herein, along with systems for operating the cartridges and performing methods to generate the population of cells suitable for formulation as a cellular therapeutic. The population of cells suitable for formulation as a cellular therapeutic can be T-cells, including CAR T-cells. The systems and methods can be largely automated.
-
公开(公告)号:US11612890B2
公开(公告)日:2023-03-28
申请号:US17452725
申请日:2021-10-28
发明人: Volker L. S. Kurz , Jason M. McEwen , Kellen C. Mobilia , Alexander J. Mastroianni , Joshua J. Cardiel Rivera
摘要: In biosciences and related fields, it can be useful to study cells in isolation so that cells having unique and desirable properties can be identified within a heterogenous mixture of cells. Processes and methods disclosed herein provide for encapsulating cells within a microfluidic device and assaying the encapsulated cells. Encapsulation can, among other benefits, facilitate analyses of cells that generate secretions of interest which would otherwise rapidly diffuse away or mix with the secretions of other cells.
-
公开(公告)号:US20220325240A1
公开(公告)日:2022-10-13
申请号:US17574459
申请日:2022-01-12
发明人: Andrew W. McFarland , Peter J. Beemiller , Guido K. Stadler , Alexander J. Mastroianni , Joshua J. Cardiel Rivera , Darcy K. Kelly-Greene , Jonathan Cloud Dragon Hubbard , Natalie C. Marks , Long Van Le , Ke-Chih Lin
摘要: Cartridges for manufacturing a population of cells suitable for formulation as a cellular therapeutic are disclosed herein, along with systems and instruments for operating the cartridges and performing methods to generate the population of cells suitable for formulation as a cellular therapeutic. The population of cells suitable for formulation as a cellular therapeutic can be immunological cells, such as T lymphocytes, including endogenous T cells (ETCs), tumor infiltrating lymphocytes (TILs), CAR T-cells, TCR engineered T-cells, or otherwise engineered T-cells. The systems and methods can be largely automated.
-
-